Results of permanent prostate brachytherapy, 13 years of experience at a single institution

Radiotherapy and Oncology

Volumn 71, Issue 1, 2004, Pages 23-28

  Battermann, Jan J ^a   Boon, Tom A ^a   Moerland, Marinus A ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

125 I Prostate brachytherapy; PSA nadir; Results; Risk groups; Treatment periods

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CAUSE OF DEATH; CONTROLLED STUDY; EVALUATION; FOLLOW UP; HUMAN; IMPLANTATION; INSTITUTIONAL CARE; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME; TECHNIQUE; TIME; TREATMENT OUTCOME; TREATMENT PLANNING;

AGED; AGED, 80 AND OVER; BRACHYTHERAPY; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL RATE;

EID: 1842423289     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2004.01.020     Document Type: Article

References (30)

1. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys. 37:1997;1035-1041.
2. Anagnostopoulos G., Baltas D. Thermoluminescent dosimetry of the selectSeed 125-I interstitial brachytherapy seed. Med Phys. 29:2000;709-716.
3. Battermann J.J. Iodine-125 seed implantation for localized prostate cancer. J Brachyther Int. 14:1998;21-27.
4. Begg C.B., Riedel E.R., Bach P.B., et al. Variations in morbidity after radical prostatectomy. N Engl J Med. 346:2002;1138-1144.
5. Blasko J.C., Grimm P.D., Sylvester J.E., et al. Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys. 46:2000;839-850.
6. Brachman D.G., Thomas T., Hilbe J., et al. Failure-free survival following brachytherapy alone or external beam irradiation alone for T1-2 prostate tumors in 2222 patients: results from a single practice. Int J Radiat Oncol Biol Phys. 48:2000;111-117.
7. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. J Am Med Assoc. 280:1998;969-974.
8. Ellis R.J., Kim E.Y., Conant R.C., et al. Radioimmunoguided imaging of prostate cancer foci with histopathological correlation. Int J Radiat Oncol Biol Phys. 49:2001;1281-1286.
9. Eng T.Y., Thomas C.R., Herman T.S. Primary radiation therapy for localized prostate cancer. Urol Oncol. 7:2002;239-257.
10. Grimm P.D., Blasko J.C., Sylvester J.E., et al. 10-Year biochemical (prostate-specific antigen) control of prostate cancer with 125-I brachytherapy. Int J Radiat Oncol Biol Phys. 51:2001;31-40.
11. Hall J.D., Boyd J.C., Lippert M.C., Theodorescu D. Why patients choose prostatectomy or brachytherapy for localized prostate cancer: results of a descriptive survey. Urology. 61:2003;402-407.
12. Hilaris B.S., Nori D., Anderson L.L. Atlas of brachytherapy. 1988;Macmillan, New York.
13. Kucway R., Vicini F., Huang R., et al. Prostate volume reduction with androgen deprivation therapy before interstitial brachytherapy. J Urol. 167:2002;2443-2447.
14. Kupelian P., Katcher J., Levin H., et al. External beam radiotherapy versus radical prostatectomy for clinical stage T1-T2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores. Cancer Sci Am. 3:1997;78-87.
15. Lederman G.S., Cavanagh W., Albert P.S., et al. Retrospective stratification of a consecutive cohort of prostate cancer patients treated with a combined regimen of external-beam radiotherapy and brachytherapy. Int J Radiat Oncol Biol Phys. 49:2001;1297-1303.
16. Lee W.R., deGuzman A.F., Tomlinson S.K., et al. Radioactive sources embedded in suture are associated with improved postimplant dosimetry in men treated with prostate brachytherapy. Radiother Oncol. 65:2002;123-127.
17. Merrick G.S., Butler W.M., Lief J.H., et al. Five-year biochemical outcome after prostate brachytherapy for hormone-naive men ≤62 years of age. Int J Radiat Oncol Biol Phys. 50:2001;1253-1257.
18. Middleton R.G., Thompson I.M., Austenfeld M.S., et al. Prostate cancer clinical guidelines panel summary report on the management of clinically localized prostate cancer. J Urol. 154:1995;2144-2148.
19. Nag S., Ciezki J.P., Cormack R., et al. Intraoperative planning and evaluation of permanent prostate brachytherapy: report of the American Brachytherapy Society. Int J Radiat Oncol Biol Phys. 51:2001;1422-1430.
20. Nath R., Anderson L.L., Luxton G., et al. Dosimetry of interstitial brachytherapy sources: recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. Med Phys. 22:1995;209-234.
21. Potters L., Cha C., Oshinsky G., et al. Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy. Cancer J Sci Am. 5:1999;301-306.
22. Potters L., Kattan M.W., Reddy C.A., et al. Monotherapy for stage T1/T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent prostate brachytherapy. Proceedings of the ASTRO 44th Annual Meeting 2002. Abstract 11. Int J Radiat Oncol Biol Phys. 54:(Suppl.):2002;9.
23. Ragde H., Korb L.J., Elgamal A.A., et al. Modern prostate brachytherapy. Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up. Cancer. 89:2000;135-141.
24. Stock R.G., Stone N.N., Cesaretti J.A. Prostate-specific antigen bounce after prostate seed implantation for localized prostate cancer: descriptions and implications. Int J Radiat Oncol Biol Phys. 56:2003;448-453.
25. Stock R.G., Stone N.N. The effect of prognostic factors on therapeutic outcome following transperineal prostate brachytherapy. Semin Surg Oncol. 13:1997;454-460.
26. Stokes S.H. Comparison of biochemical disease free survival of patients with localized carcinoma of the prostate undergoing radical prostatectomy, transperineal ultrasound-guided radioactive seed implantation, or definitive external beam irradiation. Int J Radiat Oncol Biol Phys. 47:2000;129-136.
27. Thomas M.D., Cormack R., Tempany C.M., et al. Identifying the predictors of acute urinary retention following magnetic-resonance-guided prostate brachytherapy. Int J Radiat Oncol Biol Phys. 47:2000;905-908.
28. Zelefsky M.J., Leibel S.A., Gaudin P.B., et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys. 41:1998;491-500.
29. Zelefsky M.J., Fuks Z., Hunt M. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol. 166:2001;876-881.
30. Zelefsky M.J., Yamada Y., Marion C., et al. Improved conformality and decreased toxicity with intraoperative computer-optimized transperineal ultrasound-guided prostate brachytherapy. Int J Radiat Oncol Biol Phys. 55:2003;956-963.